MIRA Pharmaceuticals reports positive Phase 1 results for Ketamir-2

May 14, 2026 8:01 AM

MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) announced positive results from its completed Phase 1 clinical trial evaluating Ketamir-2, an oral NMDA ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found